•
Jun 30, 2024

Vertex Q2 2024 Earnings Report

Vertex reported a strong second quarter with revenue growth and strategic advancements.

Key Takeaways

Vertex Pharmaceuticals reported a 6% increase in product revenue to $2.65 billion for Q2 2024, driven by TRIKAFTA/KAFTRIO. The company raised its full-year product revenue guidance to $10.65 to $10.85 billion. Key advancements include FDA acceptance of NDA for vanzacaftor triple in CF and suzetrigine for acute pain.

Product revenue increased by 6% to $2.65 billion compared to Q2 2023, driven by TRIKAFTA/KAFTRIO.

The FDA accepted NDA submissions for vanzacaftor triple in CF and suzetrigine for moderate-to-severe acute pain with Priority Review.

Vertex raised its full-year product revenue guidance to $10.65 to $10.85 billion.

GAAP and Non-GAAP net losses were $3.6 billion and $3.3 billion, respectively, primarily due to the Alpine acquisition-related charge.

Total Revenue
$2.65B
Previous year: $2.49B
+6.1%
EPS
-$12.8
Previous year: $3.89
-429.8%
GAAP effective tax rate
-6%
Previous year: 21.2%
-128.3%
Gross Profit
$2.27B
Previous year: $2.18B
+4.1%
Cash and Equivalents
$5.8B
Previous year: $11.2B
-48.4%
Free Cash Flow
-$3.82B
Previous year: $1.07B
-455.7%
Total Assets
$20.1B
Previous year: $20.3B
-1.1%

Vertex

Vertex

Vertex Revenue by Segment

Vertex Revenue by Geographic Location

Forward Guidance

Vertex raised its full year product revenue guidance from $10.55-$10.75 billion to $10.65-$10.85 billion. Vertex continues to expect combined Non-GAAP R&D and SG&A expenses to be in a range of $4.2 billion to $4.3 billion for the full year. Vertex now expects 2024 AIPR&D expenses of approximately $4.6 billion for the full year, including the Alpine acquisition-related charge in the second quarter of 2024.

Positive Outlook

  • Total product revenues are expected to be between $10.65 billion and $10.85 billion.
  • Combined Non-GAAP R&D and SG&A expenses are projected to be between $4.2 billion and $4.3 billion.
  • Guidance includes expectations for continued growth in CF.
  • Guidance includes expectations for the launch of CASGEVY in approved indications and geographies.
  • Guidance includes expectations for continued investment in multiple mid- and late-stage clinical development programs and commercial and manufacturing capabilities.

Challenges Ahead

  • AIPR&D expenses are expected to be approximately $4.6 billion, including the Alpine acquisition-related charge.
  • Full year Non-GAAP tax rate is impacted by the Alpine AIPR&D expense, which is non-deductible for tax.
  • Combined GAAP R&D and SG&A expenses are projected to be between $5.0 billion and $5.2 billion
  • Acquired IPR&D expenses is expected to be $4.6 billion
  • Impact of the Alpine acquisition affected the full year Non-GAAP tax rate